Krause Kevin Michael
- SEC CIK
- 0001916925
No open-market purchases or sales filed in the past year.
Current role at each company
- ANTX AN2 Therapeutics, Inc.Chief Strategy Officeras of Mar 29, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Krause Kevin Michael as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 11, 2024 (view filing)7:59 PM ET | Jan 9 | 2 days | Krause Kevin MichaelChief Strategy Officer | SSale | −7.42K | $20.14 | −$149.4K | −79.5%1.91K after | 10b5-1 |
| Jan 4, 2024 (view filing)6:06 PM ET | Jan 2 | 2 days | Krause Kevin MichaelChief Strategy Officer | SSale | −2.58K | $20.12 | −$52.0K | −57.4%1.91K after | 10b5-1 |